Evans et al (2008) suggested classifying cachexia as mild or greater, moderate or greater or severe depending on whether the observed weight loss is >5, >10 or >15%, respectively.
Cut-off values were those values which discriminated between patients with normal or mildly reduced RV function and those with reduced RV function, and between patients with and without at least mild or greater TR/PR with the greatest sensitivity and specificity [ 30].
We assessed the relation of these outcomes with predictor variables (FBG category [normal versus impaired versus diabetes] and IR) and clinical covariates (age, systolic blood pressure [BP], mild or greater aortic regurgitation, moderate or greater mitral regurgitation, antihypertensive medication, heart rate, and BMI).
According to WHO estimates, some 413 million people suffer from mild or greater hearing loss globally, an estimated 187 million people from moderate or greater hearing loss, and 46 million people from severe or profound hearing loss [ 1].
According to WHO estimates, some 175 million children (up to age 15 years) suffer from mild or greater hearing loss globally, an estimated 61 million children from moderate or greater hearing loss, and 7 million children from severe or profound hearing loss [ 1].
Clinical relapses (that is, increase in both global assessment and skin assessment to mild or greater) were typically accompanied by an increase in SAA and possibly CRP to greater than 30 mg/L and this pattern was observed in both children and adolescents.
In participants who began the trial with mild or greater symptoms of depression (n = 932, which included a total of 119 participants with moderate or greater symptoms), mean BDI scores fell substantially in both groups the first year, though significantly (P = 0.0045) more in ILI than DSE (Fig. 2 D ).
Relapse was defined as having a global assessment of disease activity of mild or greater or a global assessment of disease activity of minimal and an assessment of rash of mild or greater, plus CRP and/or SAA levels of > 30 mg/L.
When the prosthetic valve was oversized by ≥5%, the rate of mild or greater PVL was only 3%.
Baseline and procedural predictors of mild or greater PVL at 30 days (or at discharge if 30-day data were not available) were determined using a multivariate regression model (n = 229).
